Pubblicazioni

Autori:

Fernández-de-Las-Peñas, César; Torres-Macho, Juan; Catahay, Jesus Alfonso; Macasaet, Raymart; Velasco, Jacqueline Veronica; Macapagal, Sharina; Caldararo, Mario; Henry, Brandon Michael; Lippi, Giuseppe; Franco-Moreno, Ana; Notarte, Kin Israel

Titolo:

Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

A Stampa

Referee:

Sì

Nome rivista:

Infection

ISSN Rivista:

0300-8126

N° Volume:

52

Numero o Fascicolo:

1

Intervallo pagine:

43-58

Parole chiave:

Antiviral, Long-COVID, Nirmaltrevir/Ritonavir, Post-COVID-19, Remdesivir

Breve descrizione dei contenuti:

Purpose: Preliminary evidence suggests a potential effect of antiviral medication used during the acute COVID-19 phase for preventing long-COVID. This review investigates if having received pharmacological treatment during acute SARS-CoV-2 infection may reduce the risk of long-COVID. Methods: MEDLINE, CINAHL, PubMed, EMBASE, Web of Science databases, as well as medRxiv/bioRxiv preprint servers were searched up to July 15th, 2023. Articles comparing the presence of long-COVID symptoms between individuals who received or not a specific medication, particularly antivirals, during the acute phase of SARS-CoV-2 infection were included. Methodological quality was assessed using the Newcastle-Ottawa Scale or Cochrane's Risk of Bias (Rob) tool. Results: From 517 studies identified, 6 peer-reviewed studies and one preprint met all inclusion criteria. The sample included 2683 (n = 4) hospitalized COVID-19 survivors and 307,409 (n = 3) non-hospitalized patients. The methodological quality was high in 71% of studies (n = 5/7). Two studies investigating the effects of Nirmaltrevir/Ritonavir and three studies the effect of Remdesivir reported conflicting results on effectiveness for preventing long-COVID. Three studies investigating the effects of other medication such as Dexamethasone (n = 2) or Metformin (n = 1) found positive results of these medications for preventing long-COVID. Conclusion: Available evidence about the effect of medication treatment with antivirals during acute COVID-19 and reduced risk of developing long-COVID is conflicting. Heterogeneous evidence suggests that Remdesivir or Nirmaltrevir/Ritonavir could have a potential protective effect for long-COVID. A limited number of studies demonstrated a potential benefit of other medications such as Dexamethasone or Metformin, but more studies are needed.

Pagina Web:

https://link.springer.com/article/10.1007/s15010-023-02154-0

Id prodotto:

136733

Handle IRIS:

11562/1115927

ultima modifica:

14 luglio 2024

Citazione bibliografica:

Fernández-de-Las-Peñas, César; Torres-Macho, Juan; Catahay, Jesus Alfonso; Macasaet, Raymart; Velasco, Jacqueline Veronica; Macapagal, Sharina; Caldararo, Mario; Henry, Brandon Michael; Lippi, Giuseppe; Franco-Moreno, Ana; Notarte, Kin Israel, Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review «Infection» , vol. 52 , n. 1 , 2024 , pp. 43-58

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo